<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee KH</submitter><funding>Rural Development Administration&amp;apos;s Regional Specialized Crop Technology Development Project</funding><pagination>30467-30488</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12290619</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(28)</volume><pubmed_abstract>Age-related macular degeneration (AMD) is a progressive, late-onset, genetic (CFH, HTRA), and environmental (smoking, aging) ocular disease that is a leading cause of blindness affecting more than 200 million people worldwide. New treatments are required for fibrosis, autophagy, and microglia-driven pathologies in AMD patients for personalized medicine approaches, considering that only 10% of AMD patients are treated using the current medicine. The current study examined ninety-one compounds using a phenotypic drug discovery platform &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> to find potential drug candidates that include a new chemical entity (NCE) and extracts from plants such as , , and . The phenotypic drug discovery platform determined mitochondrial function quantitatively by measuring the ox</pubmed_abstract><journal>ACS omega</journal><pubmed_title>Phenotypic Drug Discovery Platform by Quantitative High-Throughput Screening Identifies Antiapoptotic Molecules in a Zebrafish Model of Age-Related Macular Degeneration.</pubmed_title><pmcid>PMC12290619</pmcid><funding_grant_id>PJ01696801</funding_grant_id><pubmed_authors>Jahng WJ</pubmed_authors><pubmed_authors>Stewart JM</pubmed_authors><pubmed_authors>Jung J</pubmed_authors><pubmed_authors>Jeong EH</pubmed_authors><pubmed_authors>Choo DW</pubmed_authors><pubmed_authors>Seong HW</pubmed_authors><pubmed_authors>Ahn GH</pubmed_authors><pubmed_authors>Kim JS</pubmed_authors><pubmed_authors>Ryu JM</pubmed_authors><pubmed_authors>Park B</pubmed_authors><pubmed_authors>Yoo GS</pubmed_authors><pubmed_authors>Kim YS</pubmed_authors><pubmed_authors>Samadi AF</pubmed_authors><pubmed_authors>Jee DH</pubmed_authors><pubmed_authors>Lee KH</pubmed_authors><pubmed_authors>Jin L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Phenotypic Drug Discovery Platform by Quantitative High-Throughput Screening Identifies Antiapoptotic Molecules in a Zebrafish Model of Age-Related Macular Degeneration.</name><description>Age-related macular degeneration (AMD) is a progressive, late-onset, genetic (CFH, HTRA), and environmental (smoking, aging) ocular disease that is a leading cause of blindness affecting more than 200 million people worldwide. New treatments are required for fibrosis, autophagy, and microglia-driven pathologies in AMD patients for personalized medicine approaches, considering that only 10% of AMD patients are treated using the current medicine. The current study examined ninety-one compounds using a phenotypic drug discovery platform &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i> to find potential drug candidates that include a new chemical entity (NCE) and extracts from plants such as , , and . The phenotypic drug discovery platform determined mitochondrial function quantitatively by measuring the ox</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-05-09T17:53:58.279Z</modification><creation>2026-04-08T01:08:01.875Z</creation></dates><accession>S-EPMC12290619</accession><cross_references><pubmed>40727801</pubmed><doi>10.1021/acsomega.5c02227</doi></cross_references></HashMap>